Trump administration is removing the mainstays of NCI and the federal government’s cancer program Peer review, registries, and evidence-based patient information take a big hit

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

August 07, 2026

Vol.52 No.31

In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

August 07, 2026

Vol.52 No.31

White House

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

In his latest set of sweeping tariffs on the pharmaceutical industry, President Donald Trump has announced a 200% levy on imported generic drugs by the year 2029.

July 31, 2026

Vol.52 No.30

By Jacquelyn Cobb

Cancer History Project

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Trump administration is removing the mainstays of NCI and the federal government’s cancer program

Peer review, registries, and evidence-based patient information take a big hit

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer program

Peer review, registries, and evidence-based patient information take a big hit

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Never miss an issue!

Login

Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor